HHS lets pharmacies compound BPC-157 and five other peptides: what the October 2026 policy does and doesn't do

Published October 31, 2026 by the PeptideWiki editorial team.

BPC-157 TB-500 KPV MOTS-c Semax Epitalon DSIP

An interim HHS policy filed October 28 pauses enforcement against 503A pharmacies compounding BPC-157, TB-500, KPV, MOTS-c, semax and epitalon under strict conditions. It is not an approval, and it does not cover research-use-only material.

On October 28, 2026, the Department of Health and Human Services filed an interim policy saying it will not take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound drugs from six peptide bulk substances, provided a list of conditions is met. The notice was published in the Federal Register on October 30, and comments are open for two weeks, to about November 13.

Which peptides are covered

The policy names the six substances that FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend for the 503A bulks list at its July 23–24 meeting:

FDA's own review team had recommended against adding any of the seven, citing unresolved questions about identity and characterization, limited efficacy data, and impurity and immunogenicity risks, particularly for injectable products.

What the policy requires

According to summaries of the policy document, enforcement discretion applies only when every condition is met, including:

• the peptide matches the identity and the limited route of administration set out in the policy's appendix;
• the bulk substance comes from an FDA-registered, CGMP-compliant manufacturer and has a valid certificate of analysis;
• the compounded product contains a single active ingredient and is labeled "This is a compounded drug product. Not for resale.";
• compounders report serious adverse events to FDA's MedWatch program;
• for oral products, the compounder keeps documentation that the formulation is adequately bioavailable;
• the only device packaged with the product is an FDA-cleared syringe.

HHS has described the policy as requiring patient-specific prescriptions and quality testing, and says it may revisit the policy if a safety signal or product quality problem appears.

What it does not do

• It is not an approval. None of the six becomes an FDA-approved drug, and the policy does not add them to the 503A bulks list.
• It is not the final word. Adding any of the peptides to the bulks list still requires FDA notice-and-comment rulemaking, which can take months to years. The policy is interim and can be withdrawn.
• It does not cover 503B outsourcing facilities, based on the published summaries.
• It does not cover research-use-only material. The policy's stated aim includes discouraging the use of research-use-only peptides from foreign manufacturers in place of pharmacy-compounded products. Research-grade material sold for in-vitro laboratory work sits entirely outside it.

Why the quality conditions matter

The conditions lean heavily on identity and traceability: a registered manufacturer, a valid certificate of analysis and a defined substance. That reflects the concern FDA staff raised in July. For peptides like BPC-157 and TB-500, identity testing means confirming the exact sequence and mass by mass spectrometry, and purity by HPLC, then checking that the lot on the certificate matches the lot in hand. Our guide to reading a certificate of analysis walks through each line, and the COA checker checks the numbers on a certificate.

What happens next

• Comments on the notice are due about November 13, 2026, through docket HHS-OASH-2026-0496 on regulations.gov.
• The Partnership for Safe Medicines has petitioned FDA to disregard the July vote, arguing the safety evidence is insufficient and challenging how the committee was constituted.
• The PCAC was scheduled, as of July, to review five more unapproved peptides in February 2027.

We track each step, with dates and sources, in the regulatory tracker.

Sources

1. Federal Register public inspection: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (HHS, filed Oct 28, 2026)
2. National Law Review: HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides (Oct 30, 2026)
3. AJMC: 5 Things to Know About HHS's Interim Peptide Compounding Policy (Oct 29, 2026)
4. ArentFox Schiff: The (Pep)Tides Turn: FDA Panel Recommends Six of Seven for Compounding (Jul 31, 2026)
5. FDA Law Blog (Hyman, Phelps & McNamara): PCAC Approves Four Bulk Drug Substances for the 503A List (Jul 2026)
6. Frier Levitt: FDA PCAC peptides 503A bulks list vote (Jul 24, 2026)

Educational content only, not medical advice. Compounds discussed as research materials are for laboratory research use only and are not for human or veterinary use.